An increase in the appearance of colorectal cancer incidence in younger people has prompted the American Cancer Society to revise its current screening guidelines.
Research Suggests 6-Month Adjuvant Chemotherapy May Be Superior to 3-Months in Stage III Colon Cancer, Particularly in T4 and/or N2 SubgroupsApril 06, 2018
Evidence from previous studies have shown that the legacy standard of 12-month fluoropyrimidine-based therapy could be reduced to 6 months, and perhaps even further to 3 months.
Researchers are investigating the efficacy of regorafenib in prolonging DFS among patients with stage IIIB or IIIC colon cancer compared with placebo.
Researchers evaluated BMI data from 1,087,358 men and 707,212 women in Israel to determine any link between weight in adolescence and colon/rectal cancer incidence.
Young and middle-aged colon cancer patients may be getting chemotherapy more often than is warranted.
The addition of chemotherapy after surgery did not provide a survival benefit among patients with young-onset colon cancer.
Whether the primary tumor is left- or right-sided should be considered when adjusting for treatment among patients with colon cancer.
Polycystic kidney disease (PKD) may increase one's risk of developing cancer of the liver, colon, and kidney.
A well-timed, sensitive liquid biopsy could effectively predict post-surgical recurrence of stage 2 colon cancer.
In patients with stage I, II, or III colon cancer, high Immunoscore was associated with significantly longer time to recurrence.
WNT/β-catenin pathway signaling is associated with T cell exclusion and is activated in most human solid tumors, including colon, kidney, and lung tumors.
Metastatic colorectal cancer with the primary tumor located on the left side of the colon is associated with longer survival.
Physicians and cancer organizations suggest more research is needed before the Epi proColon blood test becomes a standard screening approach.
Early mortality may be infrequent but more prevalent in patients with colon cancer in an advanced age.
Post-hoc analysis of the PETACC-8 trial tied KRAS and BRAF V600E mutations to shorter overall and disease-free survival in microsatellite stable (MSS) colon cancer.
Patients with stage 2 or 3 CDX2-negative colon cancer might benefit from adjuvant chemotherapy.
Increased incidence of grade 3 or higher fluorouracil adverse events were linked with dihydropyrimidine dehydrogenase gene DPYD variants.
Colon tumors that don't produce the protein CDX2 are more likely to recur following surgical removal in patients with stage II colon cancer.
Benefit of oxaliplatin-based adjuvant chemotherapy was confirmed at 10 years in patients with stage 2 to 3 colon cancer.
Adjuvant chemotherapy in patients with stage 3 colon cancer should be initiated within 8 weeks of surgery.
Adjuvant XELOX improved overall survival compared with bolus 5-FU/FA in patients with resected stage 3 colon cancer.
Increased travel burden is associated with a decreased likelihood of receiving adjuvant chemotherapy for treatment of colon cancer.
Higher coffee intake may be associated with significantly reduced cancer recurrence and death in patients with stage 3 colon cancer.
Cumulative exposure to statins after a diagnosis of colorectal cancer was associated with lower overall mortality.
Radial margin positivity (RMP) associated with recurrence, risk of death, shorter survival in patients with colon cancer.
Single nucleotide polymorphism in the let-7 complementary site 6 of KRAS mRNA may be a response biomarker in colorectal cancer.
Investigators recommend prioritized screening in certain pockets of the U.S. that are statistically identified as colorectal cancer (CRC) death hotspots.
Greater progress in reducing colorectal cancer incidence, mortality rates observed in Northeastern states compared to Southern states.
Patients with colorectal cancer who have the variant rs9929218 at 16q22 are at an increased risk for worse survival.
Delivery of surgical and medical oncology care in patients with colon cancer at the same hospital was associated with lower costs.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib